Pre-made Romosozumab benchmark antibody ( Whole mAb, anti-SOST therapeutic antibody, Anti-CDD/DAND6/VBCH Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Romosozumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-493-1mg	1mg	3090
GMP-Bios-ab-493-10mg	10mg	Inquiry
GMP-Bios-ab-493-100mg	100mg	Inquiry
GMP-Bios-ab-493-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Romosozumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody
INN Name	Romosozumab
Target	SOST
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2011
Year Recommended	2012
Companies	ChiroscienceGroup plc;Amgen;UCB
Conditions Approved	Male osteoporosis;Postmenopausal osteoporosis
Conditions Active	na
Conditions Discontinued	Fracture
Development Tech	na